Analyst Scoreboard: 4 Ratings For Harpoon Therapeutics
4 analysts have expressed a variety of opinions on Harpoon Therapeutics (NASDAQ:HARP) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 1 | 2 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 1 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Harpoon Therapeutics, revealing an average target of $20.25, a high estimate of $23.00, and a low estimate of $12.00. This upward trend is apparent, with the current average reflecting a 86.98% increase from the previous average price target of $10.83.
Decoding Analyst Ratings: A Detailed Look
A comprehensive examination of how financial experts perceive Harpoon Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Yigal Nochomovitz | Citigroup | Raises | Neutral | $23.00 | $13.00 |
| Swayampakula Ramakanth | HC Wainwright & Co. | Raises | Neutral | $23.00 | $12.00 |
| Hartaj Singh | Oppenheimer | Announces | Outperform | $23.00 | - |
| Swayampakula Ramakanth | HC Wainwright & Co. | Raises | Buy | $12.00 | $7.50 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Harpoon Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Harpoon Therapeutics compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Harpoon Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
For valuable insights into Harpoon Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Harpoon Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Unveiling the Story Behind Harpoon Therapeutics
Harpoon Therapeutics Inc is a clinical-stage immunotherapy company. It is engaged in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The company's pipeline products include HPN424, HPN536, HPN217, and others.
Key Indicators: Harpoon Therapeutics's Financial Health
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Harpoon Therapeutics's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2023, the company experienced a revenue decline of approximately -67.33%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Harpoon Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -40.51% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -47.8%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Harpoon Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.25% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 3.19, caution is advised due to increased financial risk.
Analyst Ratings: What Are They?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.